1.80
1.64%
-0.03
After Hours:
1.79
-0.01
-0.56%
Nektar Therapeutics stock is currently priced at $1.80, with a 24-hour trading volume of 1.45M.
It has seen a -1.64% decreased in the last 24 hours and a +20.81% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.82 pivot point. If it approaches the $1.78 support level, significant changes may occur.
Previous Close:
$1.83
Open:
$1.83
24h Volume:
1.45M
Market Cap:
$330.52M
Revenue:
$90.12M
Net Income/Loss:
$-276.06M
P/E Ratio:
-1.1043
EPS:
-1.63
Net Cash Flow:
$-193.47M
1W Performance:
+12.50%
1M Performance:
+20.81%
6M Performance:
+256.65%
1Y Performance:
+151.75%
Nektar Therapeutics Stock (NKTR) Company Profile
Name
Nektar Therapeutics
Sector
Industry
Phone
415-482-5300
Address
455 Mission Bay Boulevard South, San Francisco, CA
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-10-23 | Upgrade | Jefferies | Underperform → Hold |
Feb-24-23 | Downgrade | Jefferies | Hold → Underperform |
Aug-08-22 | Downgrade | JP Morgan | Neutral → Underweight |
May-31-22 | Resumed | Jefferies | Hold |
Apr-18-22 | Downgrade | Goldman | Neutral → Sell |
Mar-15-22 | Downgrade | Cowen | Outperform → Market Perform |
Mar-15-22 | Downgrade | Mizuho | Buy → Neutral |
Mar-14-22 | Downgrade | BTIG Research | Buy → Neutral |
Mar-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
Mar-14-22 | Downgrade | Stifel | Buy → Hold |
Mar-14-22 | Downgrade | William Blair | Outperform → Mkt Perform |
Mar-09-22 | Upgrade | Oppenheimer | Perform → Outperform |
Nov-08-21 | Upgrade | The Benchmark Company | Hold → Buy |
Sep-10-21 | Initiated | BofA Securities | Neutral |
Jun-28-21 | Upgrade | Stifel | Hold → Buy |
May-18-21 | Resumed | Goldman | Neutral |
Feb-22-21 | Downgrade | The Benchmark Company | Buy → Hold |
Jan-06-21 | Initiated | Stifel | Hold |
Sep-14-20 | Initiated | JP Morgan | Neutral |
Jun-10-20 | Downgrade | CFRA | Hold → Sell |
May-12-20 | Reiterated | H.C. Wainwright | Neutral |
Apr-22-20 | Initiated | The Benchmark Company | Buy |
Mar-30-20 | Upgrade | Goldman | Sell → Neutral |
Mar-04-20 | Initiated | Barclays | Overweight |
Feb-03-20 | Upgrade | Mizuho | Neutral → Buy |
Oct-24-19 | Initiated | Oppenheimer | Perform |
Oct-08-19 | Downgrade | Goldman | Buy → Sell |
Aug-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
Aug-09-19 | Downgrade | Jefferies | Buy → Hold |
Aug-09-19 | Downgrade | Mizuho | Buy → Neutral |
Mar-15-19 | Initiated | SVB Leerink | Mkt Perform |
Dec-13-18 | Initiated | Goldman | Buy |
Jun-11-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
Jun-04-18 | Reiterated | H.C. Wainwright | Buy |
Apr-20-18 | Initiated | Seaport Global Securities | Buy |
Apr-13-18 | Resumed | Piper Jaffray | Overweight |
Apr-06-18 | Reiterated | Mizuho | Buy |
Apr-02-18 | Resumed | H.C. Wainwright | Buy |
View All
Nektar Therapeutics Stock (NKTR) Latest News
Nektar stops clinical trials for key cancer drug, shares tumble - Yahoo Movies Canada
Yahoo Movies Canada
Nektar stops clinical trials for key cancer drug, shares tumble - Yahoo Canada Shine On
Yahoo Canada Shine On
Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) Major Shareholder Sells 56,000 Shares of Stock - MarketBeat
MarketBeat
Deep Track Capital sells $99.6k of Nektar Therapeutics stock - Investing.com
Investing.com
Nektar (NKTR) Inks Deal With Daiichi Sankyo for Onzeald - Yahoo News UK
Yahoo News UK
Here's Why Nektar Therapeutics Stock Gained 13.6% in June - Yahoo News UK
Yahoo News UK
Nektar Therapeutics Stock (NKTR) Financials Data
Nektar Therapeutics (NKTR) Revenue 2024
NKTR reported a revenue (TTM) of $90.12 million for the quarter ending December 31, 2023, a -2.10% decline year-over-year.
Nektar Therapeutics (NKTR) Net Income 2024
NKTR net income (TTM) was -$276.06 million for the quarter ending December 31, 2023, a +25.03% increase year-over-year.
Nektar Therapeutics (NKTR) Cash Flow 2024
NKTR recorded a free cash flow (TTM) of -$193.47 million for the quarter ending December 31, 2023, a +37.53% increase year-over-year.
Nektar Therapeutics (NKTR) Earnings per Share 2024
NKTR earnings per share (TTM) was -$1.46 for the quarter ending December 31, 2023, a +25.89% growth year-over-year.
About Nektar Therapeutics
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology. It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia. In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis. Further, it is developing SEMPRANA to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with AstraZeneca AB, Shire plc, Pfizer Inc., Amgen Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, Bristol-Myers Squibb Company, and Takeda Pharmaceutical Company Limited. The company was founded in 1990 and is headquartered in San Francisco, California.
Cap:
|
Volume (24h):